Market-Moving Exclusives Archives - Page 12 of 22

1 minute read

EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids

August 29, 8:54 AM

NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-conc

NRXS

1 minute read

EXCLUSIVE: Ocean Biomedical Announces New Patent For Fibrosis Candidate Catering To One Of Leading Death Causes In US

By Vandana Singh

August 29, 7:30 AM

Ocean Biomedical Inc (NASDAQ: OCEA) announced that the United States Patent and Trademark Office has issued a patent covering Ocean’s anti-Chitinase 1 small molecule candidate.

OCEA

1 minute read

EXCLUSIVE: ProSomnus’ Device Therapy Better Than Philip’s Device(s) For Sleep-Related Breathing Disorder, Study Shows

By Vandana Singh

August 23, 7:30 AM

ProSomnus Inc (NASDAQ: OSA), a provider of CPAP alternatives for Obstructive Sleep Apnea, announced updated data presented at the ProSleep Conference earlier this month. The updated data indicate the FLOSAT study is on track to achieve all endpoints.

OSA

1 minute read

EXCLUSIVE: HeartSciences Announces Expansion of Artificial Intelligence Patent Portfolio

By Vandana Singh

August 17, 8:36 AM

Heart Test Laboratories Inc d/b/a HeartSciences (NASDAQ: HSCS) has been issued a notice of patent allowance from the European Patent Office.

HSCS

1 minute read

EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer

By Vandana Singh

August 11, 6:00 AM

Plus Therapeutics Inc (NASDAQ: PSTV) reported data from the ReSPECT-LM study evaluating the company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for

PSTV

1 minute read

EXCLUSIVE: Ocean Biomedical Unveils Comprehensive Updates On Its Cancer, Malaria, Fibrosis Programs

By Vandana Singh

August 10, 7:30 AM

Ocean Biomedical Inc (NASDAQ: OCEA) shared an update on its broad range of programs in malaria, fibrosis, and multiple cancers. Oncology Program:

OCEA

1 minute read

EXCLUSIVE: ProSomnus Reports Much Smaller Than Expected Q2 Loss, Revenues Inline With Consensus

By Vandana Singh

August 3, 7:30 AM

Obstructive Sleep Apnea treatment provider ProSomnus Inc (NASDAQ: OSA) reported Q2 revenues of $6.9 million, up 43% Y/Y and a sequential revenue increase of 19%, slightly beating the consensus of $6.4 million.

OSA

1 minute read

EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio

By Vandana Singh

August 1, 8:30 AM

Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of its overarching strategy to strengthen its IP portfolio further.

CMND

3 minute read

Cash Flow Chronicles: Analyst Dissects Canadian Cannabis Balance Sheets, Market Trends Vs. The US

By Nicolas Jose Rodriguez

July 27, 9:05 AM

Benzinga recently reviewed the balance sheet and cash flow trends of Canadian LPs (licensed producers). Zuanic & Associates presents crucial factual key findings:

ACB

1 minute read

EXCLUSIVE: Smart for Life Inks Agreement With Boxout For Nationwide Distribution Of Sports Illustrated Nutrition Products

By Shivani Kumaresan

July 27, 8:47 AM

Nutraceutical company Smart for Life Inc (NASDAQ: SMFL) said it has entered into a distribution agreement with health and wellness products distributor, Boxout.

SMFL